179 related articles for article (PubMed ID: 24473900)
1. Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.
Martins LR; Perera Y; Lúcio P; Silva MG; Perea SE; Barata JT
Oncotarget; 2014 Jan; 5(1):258-63. PubMed ID: 24473900
[TBL] [Abstract][Full Text] [Related]
2. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.
Martins LR; Lúcio P; Silva MC; Anderes KL; Gameiro P; Silva MG; Barata JT
Blood; 2010 Oct; 116(15):2724-31. PubMed ID: 20660292
[TBL] [Abstract][Full Text] [Related]
3. On CK2 regulation of chronic lymphocytic leukemia cell viability.
Martins LR; Lúcio P; Silva MC; Gameiro P; Silva MG; Barata JT
Mol Cell Biochem; 2011 Oct; 356(1-2):51-5. PubMed ID: 21750986
[TBL] [Abstract][Full Text] [Related]
4. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
Gottardo MF; Capobianco CS; Sidabra JE; Garona J; Perera Y; Perea SE; Alonso DF; Farina HG
Sci Rep; 2020 Sep; 10(1):14689. PubMed ID: 32895446
[TBL] [Abstract][Full Text] [Related]
6. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815
[TBL] [Abstract][Full Text] [Related]
7. CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.
Russo M; Milito A; Spagnuolo C; Carbone V; Rosén A; Minasi P; Lauria F; Russo GL
Oncotarget; 2017 Jun; 8(26):42571-42587. PubMed ID: 28489572
[TBL] [Abstract][Full Text] [Related]
8. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
[TBL] [Abstract][Full Text] [Related]
9. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
10. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.
Gomes AM; Soares MV; Ribeiro P; Caldas J; Póvoa V; Martins LR; Melão A; Serra-Caetano A; de Sousa AB; Lacerda JF; Barata JT
Haematologica; 2014 Jun; 99(6):1062-8. PubMed ID: 24561792
[TBL] [Abstract][Full Text] [Related]
11. Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Perera Y; Melão A; Ramón AC; Vázquez D; Ribeiro D; Perea SE; Barata JT
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471246
[TBL] [Abstract][Full Text] [Related]
12. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Song C; Gowda C; Pan X; Ding Y; Tong Y; Tan BH; Wang H; Muthusami S; Ge Z; Sachdev M; Amin SG; Desai D; Gowda K; Gowda R; Robertson GP; Schjerven H; Muschen M; Payne KJ; Dovat S
Blood; 2015 Oct; 126(15):1813-22. PubMed ID: 26219304
[TBL] [Abstract][Full Text] [Related]
13. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE; Baladron I; Garcia Y; Perera Y; Lopez A; Soriano JL; Batista N; Palau A; Hernández I; Farina H; Garcia I; Gonzalez L; Gil J; Rodriguez A; Solares M; Santana A; Cruz M; Lopez M; Valenzuela C; Reyes O; López-Saura PA; González CA; Diaz A; Castellanos L; Sanchez A; Betancourt L; Besada V; González LJ; Garay H; Gómez R; Gómez DE; Alonso DF; Perrin P; Renualt JY; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2011 Oct; 356(1-2):45-50. PubMed ID: 21735096
[TBL] [Abstract][Full Text] [Related]
14. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
15. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.
Shehata M; Schnabl S; Demirtas D; Hilgarth M; Hubmann R; Ponath E; Badrnya S; Lehner C; Hoelbl A; Duechler M; Gaiger A; Zielinski C; Schwarzmeier JD; Jaeger U
Blood; 2010 Oct; 116(14):2513-21. PubMed ID: 20576813
[TBL] [Abstract][Full Text] [Related]
16. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
[TBL] [Abstract][Full Text] [Related]
17. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome.
Perera Y; Ramos Y; Padrón G; Caballero E; Guirola O; Caligiuri LG; Lorenzo N; Gottardo F; Farina HG; Filhol O; Cochet C; Perea SE
Mol Cell Biochem; 2020 Jul; 470(1-2):63-75. PubMed ID: 32405972
[TBL] [Abstract][Full Text] [Related]
18. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.
Barata JT
Adv Enzyme Regul; 2011; 51(1):37-49. PubMed ID: 21035501
[TBL] [Abstract][Full Text] [Related]
19. Regulation of taurine homeostasis by protein kinase CK2 in mouse fibroblasts.
Hansen DB; Guerra B; Jacobsen JH; Lambert IH
Amino Acids; 2011 Apr; 40(4):1091-106. PubMed ID: 20827495
[TBL] [Abstract][Full Text] [Related]
20. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
